Guide contents
Open in calculatorCompound briefing
KLOW is a research-grade compounded blend combining four complementary peptides — KPV (anti-inflammatory tripeptide), Larazotide (tight-junction modulator), Orexin-A (wakefulness and metabolic regulator) and GHK-Cu (regenerative copper tripeptide). Designed as a single-injection regenerative stack, it is studied primarily for gut-barrier integrity, systemic inflammation and skin/connective remodelling.
The research question
KLOW combines compounds with markedly different biological targets. A sound research record should therefore report the amount of each constituent, not only total vial mass, and avoid treating unrelated mechanisms as proof of synergy.
Mechanism & research themes
GHK-Cu drives collagen synthesis and broad transcriptomic remodelling. Larazotide antagonises zonulin to tighten intestinal tight junctions. KPV provides α-MSH–derived anti-inflammatory activity via NF-κB suppression. Orexin-A modulates wakefulness, appetite and energy expenditure via OX1R/OX2R receptors.
Combined gut-barrier, anti-inflammatory and regenerative activity
Single-injection convenience for stacked protocols
Skin and connective remodelling via the GHK-Cu component
Tight-junction support relevant to leaky-gut research models
Anti-inflammatory effect across NF-κB and α-MSH pathways
Daytime energy and appetite modulation via Orexin-A
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Each constituent has a separate evidence base and exposure profile. There is no robust controlled evidence for this four-compound preparation as a single intervention.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 200–500mcg of the blend subcutaneously once daily, typically morning administration due to the orexin component. Cycles run 4–8 weeks.
Reported persistence
Variable across constituents — GHK-Cu approximately 1 hour, KPV short, Larazotide local GI activity, Orexin-A approximately 30–60 minutes plasma.
Calculator starting point
0.3 mg per reference dose
5 doses per week · 6-week cycle
3 mL default reconstitution volume
Recovery blend; commonly 4–6 weeks at 5×/week.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate KLOWLaboratory handling
Reconstitution reference
Reconstitute an 80mg vial with 4–5mL bacteriostatic water for approximately 16–20mg/mL working concentration. Swirl gently; the solution may appear faintly tinted due to the copper component.
Storage reference
Lyophilised: 2–8°C, stable 12–18 months. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Avoid evening administration — orexin component is wakefulness-promoting.
Compounded blends lack standalone clinical trial data; outcomes are extrapolated from constituents.
Avoid in copper-metabolism disorders (Wilson's disease) due to the GHK-Cu component.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading